Liu S, Lin H, Zhang K, Zhou Q, Shen Y
J Ovarian Res. 2025; 18(1):32.
PMID: 39972314
PMC: 11837690.
DOI: 10.1186/s13048-025-01620-7.
Sato S, Shintani D, Kaneda Y, Nakamura R, Katoh T, Yano M
Int J Clin Oncol. 2025; .
PMID: 39937426
DOI: 10.1007/s10147-024-02658-1.
Yao Y, Zhang J, Huang K, Peng Y, Cheng S, Liu S
J Nanobiotechnology. 2025; 23(1):83.
PMID: 39910555
PMC: 11796236.
DOI: 10.1186/s12951-025-03165-9.
Wang Y, Zhang C, Zeng H, Wang L, Wang Z, Han Z
Cancer Immunol Immunother. 2025; 74(3):103.
PMID: 39904884
PMC: 11794933.
DOI: 10.1007/s00262-025-03951-2.
Silverwood S, Backer G, Galloway A, Reid K, Jeter A, Harrison M
BMJ Oncol. 2025; 3(1):e000404.
PMID: 39886168
PMC: 11261692.
DOI: 10.1136/bmjonc-2024-000404.
Spatial single-cell maps reveal ST6GAL1 promoting ovarian cancer metastasis.
Qin L, Jiang Z, Yang C, Song R, Chen P, Xu W
Glycoconj J. 2025; 42(1):27-40.
PMID: 39883364
DOI: 10.1007/s10719-025-10177-y.
Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.
Villegas-Vazquez E, Marin-Carrasco F, Reyes-Hernandez O, Baez-Gonzalez A, Bustamante-Montes L, Padilla-Benavides T
Front Oncol. 2025; 14:1514120.
PMID: 39876896
PMC: 11772297.
DOI: 10.3389/fonc.2024.1514120.
The HOX Gene Family's Role as Prognostic and Diagnostic Biomarkers in Hematological and Solid Tumors.
Kopec K, Quaranto D, DeSouza N, Jarboe T, Islam H, Moscatello A
Cancers (Basel). 2025; 17(2).
PMID: 39858044
PMC: 11763641.
DOI: 10.3390/cancers17020262.
Incorporating genotype information in a precise prediction model for platinum sensitivity in epithelial ovarian cancer.
Du N, Li Y, Zheng H, Liu Y, Liu L, Xie J
Front Oncol. 2025; 14():1461772.
PMID: 39839768
PMC: 11746020.
DOI: 10.3389/fonc.2024.1461772.
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed....
Mukherjee U, Hockings H, Counsell N, Patel A, Narayanan P, Wilkinson K
BMJ Open. 2025; 14(12):e091262.
PMID: 39806715
PMC: 11667365.
DOI: 10.1136/bmjopen-2024-091262.
Automatic segmentation model and machine learning model grounded in ultrasound radiomics for distinguishing between low malignant risk and intermediate-high malignant risk of adnexal masses.
Liu L, Cai W, Zheng F, Tian H, Li Y, Wang T
Insights Imaging. 2025; 16(1):14.
PMID: 39804536
PMC: 11729609.
DOI: 10.1186/s13244-024-01874-7.
SUGT1 is a prognostic biomarker and is associated with immune infiltrates in ovarian cancer.
Ge L, Liu X, Zhang L, Zhang J, Song G
Eur J Med Res. 2025; 30(1):21.
PMID: 39794869
PMC: 11724497.
DOI: 10.1186/s40001-024-02232-5.
MiR-675 Inhibits Primary Ovarian Tumor Growth and Metastasis by Suppressing EMT and TGFβ Signaling.
Zhao X, Liu Z, Li Y, Song S, Wang B, Pfeffer L
J Cancer. 2025; 16(1):55-65.
PMID: 39744561
PMC: 11660139.
DOI: 10.7150/jca.102654.
Sex hormones and immune regulation in ovarian cancer.
Zhao R, Lian W, Xu Q
Discov Oncol. 2024; 15(1):849.
PMID: 39738765
PMC: 11688266.
DOI: 10.1007/s12672-024-01675-w.
Challenges in Implementing Comprehensive Precision Medicine Screening for Ovarian Cancer.
Moffitt L, Karimnia N, Wilson A, Stephens A, Ho G, Bilandzic M
Curr Oncol. 2024; 31(12):8023-8038.
PMID: 39727715
PMC: 11674382.
DOI: 10.3390/curroncol31120592.
Nanotheranostics for gynecological cancers: a path forward for Africa.
Aza M, Suberu A, Balogun M, Adegbola G, Sankoh M, Oyediran T
Med Oncol. 2024; 42(1):34.
PMID: 39704911
DOI: 10.1007/s12032-024-02582-4.
Nomogram for predicting the early death of patients with stage IV ovarian cancer: a retrospective analysis of the SEER database.
Chen P, Zheng S, Zhang L
Transl Cancer Res. 2024; 13(11):5845-5855.
PMID: 39697763
PMC: 11651799.
DOI: 10.21037/tcr-24-625.
Cytotoxicity of natural and synthetic cannabinoids and their synergistic antiproliferative effects with cisplatin in human ovarian cancer cells.
Chen Y, Li H, Liu J, Ni J, Deng Q, He H
Front Pharmacol. 2024; 15:1496131.
PMID: 39660007
PMC: 11629013.
DOI: 10.3389/fphar.2024.1496131.
Performance of International Ovarian Tumor Analysis (IOTA) predictive models in preoperative discrimination between benign and malignant adnexal lesions: preliminary outcomes in a Tertiary Care Hospital in Greece.
Kougioumtsidou A, Karavida A, Mamopoulos A, Dagklis T, Tsakiridis I, Kopatsaris S
Arch Gynecol Obstet. 2024; 311(1):113-122.
PMID: 39658706
DOI: 10.1007/s00404-024-07859-7.
Decoding the Ferroptosis-Related Gene Signatures and Immune Infiltration Patterns in Ovarian Cancer: Bioinformatic Prediction Integrated with Experimental Validation.
Zhang B, Guo B, Kong H, Yang L, Yan H, Liu J
J Inflamm Res. 2024; 17:10333-10346.
PMID: 39654865
PMC: 11626233.
DOI: 10.2147/JIR.S498740.